Cobalt Chloride Induced Apoptosis by Inhibiting GPC3 Expression Via the HIF-1α/c-Myc Axis in HepG2 Cells

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Dec 12

PMID 31824173

Citations 5

Authors

Yaoyao Tong

Kun Tong

Qinghong Zhu

Yuqin Wu

Yi Yang

Jicai Zhang

Pei Hu

Shirong Yan

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the role of glypican-3 (GPC3) in cobalt chloride (CoCl)-induced cell apoptosis in hepatocellular carcinoma.

Methods: HepG2 cells were treated with CoCl in the absence or presence of GPC3 plasmid transfection. Cell viability and apoptosis were assessed by MTT assay and flow cytometry, respectively. The expression of GPC3, hypoxia-inducible factor 1α (HIF-1α), c-myc, sp1, poly-ADP-ribose polymerase (PARP) and caspase-3 was determined by real-time PCR, Western blotting, and immunofluorescence after the cells were treated with different concentrations of CoCl or siRNA targeting HIF-1α.

Results: CoCl significantly inhibited the proliferation of HepG2 cells and induced apoptosis. Additionally, the expression of GPC3 mRNA and protein was decreased, and overexpression of GPC3 attenuated the tumour inhibiting effects. Further studies showed that CoCl increased the expression of HIF-1α while reducing the expression of sp1 and c-myc; knockdown of HIF-1α elevated the expression of GPC3, sp1, and c-myc.

Conclusion: CoCl inhibited the growth of HepG2 cells through downregulation of GPC3 expression via the HIF-1α/c-myc axis.

Citing Articles

COE targets EphA2 to inhibit vasculogenic mimicry formation induced by hypoxia in hepatocellular carcinoma.

Chen J, Dai S, Wu S, Wu M, Yu K, Liu J Front Pharmacol. 2024; 15:1421470.

PMID: 39050762 PMC: 11266089. DOI: 10.3389/fphar.2024.1421470.

Impact of HIF1-α/TGF-β/Smad-2/Bax/Bcl2 pathways on cobalt chloride-induced cardiac and hepatorenal dysfunction.

Kadry M, Ali H Future Sci OA. 2023; 9(8):FSO874.

PMID: 37621844 PMC: 10445593. DOI: 10.2144/fsoa-2023-0050.

Soy Isoflavones Protect Neuronal PC12 Cells against Hypoxic Damage through Nrf2 Activation and Suppression of p38 MAPK and AKT-mTOR Pathways.

Zhang Y, Yin L, Dong J, Xia X Antioxidants (Basel). 2022; 11(10).

PMID: 36290760 PMC: 9598610. DOI: 10.3390/antiox11102037.

The Effects of Hypoxia-Reoxygenation in Mouse Digital Flexor Tendon-Derived Cells.

Chen C, Mao W, Wu Y Oxid Med Cell Longev. 2021; 2020:7305392.

PMID: 33456674 PMC: 7787768. DOI: 10.1155/2020/7305392.

Effect of isoform-specific HIF-1α and HIF-2α antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model.

Vanderborght B, De Muynck K, Lefere S, Geerts A, Degroote H, Verhelst X Oncotarget. 2021; 11(48):4504-4520.

PMID: 33400730 PMC: 7721613. DOI: 10.18632/oncotarget.27830.

References

Wilson G, Tennant D, McKeating J . Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J Hepatol. 2014; 61(6):1397-406. DOI: 10.1016/j.jhep.2014.08.025. View

Tahon A, El-Ghanam M, Zaky S, Emran T, Bersy A, El-Raey F . Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients. J Gastrointest Cancer. 2018; 50(3):434-441. DOI: 10.1007/s12029-018-0095-2. View

Qi X, Wu D, Cui H, Ma N, Su J, Wang Y . Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells. Mol Med Rep. 2014; 10(6):3177-84. DOI: 10.3892/mmr.2014.2600. View

Kawaida M, Yamazaki K, Tsujikawa H, Fukuma M, Abe Y, Kitago M . Diffuse and canalicular patterns of glypican-3 expression reflect malignancy of hepatocellular carcinoma. Pathol Int. 2019; 69(3):125-134. DOI: 10.1111/pin.12767. View

Li L, Jin R, Zhang X, Lv F, Liu L, Liu D . Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology. 2012; 56(4):1380-90. DOI: 10.1002/hep.25891. View

Munoz-Sanchez J, Chanez-Cardenas M . The use of cobalt chloride as a chemical hypoxia model. J Appl Toxicol. 2018; 39(4):556-570. DOI: 10.1002/jat.3749. View

Li N, Wei L, Liu X, Bai H, Ye Y, Li D . A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice. Hepatology. 2019; 70(4):1231-1245. PMC: 6783318. DOI: 10.1002/hep.30646. View

Lin D, Wu J . Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target. World J Gastroenterol. 2015; 21(42):12171-8. PMC: 4641134. DOI: 10.3748/wjg.v21.i42.12171. View

Li Y, Liu Z, Wang J, Yu J, Li Z, Yang H . Receptor-Interacting Protein Kinase 3 Deficiency Recruits Myeloid-Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C-X-C Motif) Ligand 1-Chemokine (C-X-C Motif) Receptor 2 Axis. Hepatology. 2019; 70(5):1564-1581. PMC: 6900048. DOI: 10.1002/hep.30676. View

10.

Gao W, Ho M . The role of glypican-3 in regulating Wnt in hepatocellular carcinomas. Cancer Rep. 2012; 1(1):14-19. PMC: 3343874. View

11.

Gordan J, Thompson C, Simon M . HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell. 2007; 12(2):108-13. PMC: 3215289. DOI: 10.1016/j.ccr.2007.07.006. View

12.

Chen C, Lou T . Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget. 2017; 8(28):46691-46703. PMC: 5542303. DOI: 10.18632/oncotarget.17358. View

13.

Fer N, Melillo G . The HIF-1α-c-Myc pathway and tumorigenesis: evading the apoptotic gate-keeper. Cell Cycle. 2011; 10(19):3228. PMC: 3356795. DOI: 10.4161/cc.10.19.17049. View

14.

May M . Statistics: Attacking an epidemic. Nature. 2014; 509(7502):S50-1. DOI: 10.1038/509S50a. View

15.

Lee M, Lapham A, Brimmell M, Wilkinson H, Packham G . Inhibition of proteasomal degradation of Mcl-1 by cobalt chloride suppresses cobalt chloride-induced apoptosis in HCT116 colorectal cancer cells. Apoptosis. 2008; 13(8):972-82. DOI: 10.1007/s10495-008-0229-2. View

16.

To K, Huang L . An efficient way of studying protein-protein interactions involving HIF-α, c-Myc, and Sp1. Methods Mol Biol. 2013; 1012:77-84. DOI: 10.1007/978-1-62703-429-6_6. View

17.

Wang Z, Han Y, Huang S, Wang M, Zhou W, Li H . Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. Amino Acids. 2017; 50(2):309-320. DOI: 10.1007/s00726-017-2517-z. View

18.

Hamaoka M, Kobayashi T, Tanaka Y, Mashima H, Ohdan H . Clinical significance of glypican-3-positive circulating tumor cells of hepatocellular carcinoma patients: A prospective study. PLoS One. 2019; 14(5):e0217586. PMC: 6541303. DOI: 10.1371/journal.pone.0217586. View

19.

Zhou F, Shang W, Yu X, Tian J . Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2017; 38(2):741-767. DOI: 10.1002/med.21455. View

20.

Lee H, Yeon J, Suh S, Lee S, Yoon E, Kang K . Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014; 8(2):177-85. PMC: 3964269. DOI: 10.5009/gnl.2014.8.2.177. View